Protective Role of Major Histocompatibility Complex Class II Eb\(^d\) Transgene on Collagen-induced Arthritis

By Miguel A. Gonzalez-Gay, Gerald H. Nabozny, Michael J. Bull, Eric Zanelli, John Douhan III, Marie M. Griffiths, Laurie H. Glimcher, Harvinder S. Luthra, and Chella S. David

Summary

Collagen-induced arthritis (CIA) is an animal model of autoimmune inflammatory polyarthritis that has features similar to rheumatoid arthritis (RA). Much like RA, susceptibility to mouse CIA is influenced by the major histocompatibility complex (MHC), H-2, and restricted to the H-2\(^q\) and H-2\(^r\) haplotypes. Whereas the role of the H-2A molecule in susceptibility to CIA is well established, little is known about the role of H-2E molecule in the disease. In this study, we analyzed the effect of a transgenic Eb\(^d\) molecule on CIA susceptibility in a recombinant mouse B10.RQB3, which expresses the CIA susceptible A\(^q\) genes and an Eb\(^d\) gene, but does not produce an E molecule since Eb\(^q\) is nonfunctional. In the presence of an Eb\(^d\) transgene, a viable E molecule is generated. Whereas B10.RQB3 were susceptible to CIA, B10.RQB3-Eb\(^d\) showed a dramatic reduction in the incidence of arthritis as well as a decrease in the level of anti-mouse and anti-bovine CII antibodies in their serum. No clear cut differences in the expression of T cell receptor (TCR) \(\gamma\beta\) was observed between Eb\(^d\) and Eb\(^q\) transgenic mice. Mechanisms underlying the protective effect of Eb\(^d\) transgenic molecule on CIA may shed light on how HLA-DR molecules influence human RA.

Materials and Methods

Mice. All the mice used in this study were bred and maintained in our pathogen-free mouse colony and were 8-12 wk of age at the start of the experiment.

Generation of Eb\(^d\) Transgenic Mice. A 15.7-kb DNA fragment isolated from a BALB/c cosmid library covering the entire Eb\(^d\)
gene with 4.1 kb of 5'-flanking regulatory region (13) was microinjected into (SWR × B10.M)F, embryos as described (14). Transgene positive mice were identified by Southern blot analysis. The Eb\(^a\) gene was introduced into the B10.RQB3 mice by backcrossing. Expression of the Eb\(^a\) molecule was analyzed by flow cytometry as described below (15). The transgenic mice used in these studies were from the N9-N10 backcross population.

**Flow Cytometry.** Analysis of Eb\(^a\) and V\(\beta\) TCR expression on PBL were determined by flow cytometry as previously described (15). Briefly, PBL were isolated by ficoll separation, washed, and then incubated with the Eb\(^a\)-specific mAb 34-1-4S (16) for 30 min at 4°C. After washing, the cells were incubated with FITC goat anti-mouse IgG (Accurate Chemicals and Scientific Corp., Westbury, NY) for 30 min at 4°C, washed, and then fixed with 1% paraformaldehyde before analysis. Analysis for V\(\beta\) TCR was done using the following mAbs: B20.6, anti-V\(\beta\)2; KT4-10, anti-V\(\beta\)4; MR9-4, anti-V\(\beta\)5.1-5.2; 44-22-1, anti-V\(\beta\)6; TR-310, anti-V\(\beta\)7; F23.2, anti-V\(\beta\)8.2; MR10-2, anti-V\(\beta\)9; KT11, anti-V\(\beta\)11; and 14.2, anti-V\(\beta\)14. Second antibodies consisted of FITC-conjugated mouse anti-rat IgG or IgM or goat anti-mouse IgG. T cell subsets were identified by incubation with mAbs specific for mouse CD4 and CD8 conjugated to R-Phycoerythrin and Red 613, respectively (GIBCO BRL, Gaithersburg, MD). Single-color (for Eb\(^a\)) and three-color (for V\(\beta\) TCR) flow cytometric analysis was performed using a FACS® IV flow cytometer (Becton Dickinson & Co., Mountain View, CA).

**Induction and Quantification of Arthritis.** Bovine CII (BII), prepared as previously described (3), was dissolved in 0.1 M acetic acid and then emulsified with the Eb\(^a\)-specific mAb 34-1-4S (16) for 30 min at 4°C. After washing, the cells were incubated with FITC goat anti-mouse IgG (Accurate Chemicals and Scientific Corp., Westbury, NY) for 30 min at 4°C, washed, and then fixed with 1% paraformaldehyde before analysis. Analysis for V\(\beta\) TCR was done using the following mAbs: B20.6, anti-V\(\beta\)2; KT4-10, anti-V\(\beta\)4; MR9-4, anti-V\(\beta\)5.1-5.2; 44-22-1, anti-V\(\beta\)6; TR-310, anti-V\(\beta\)7; F23.2, anti-V\(\beta\)8.2; MR10-2, anti-V\(\beta\)9; KT11, anti-V\(\beta\)11; and 14.2, anti-V\(\beta\)14. Second antibodies consisted of FITC-conjugated mouse anti-rat IgG or IgM or goat anti-mouse IgG. T cell subsets were identified by incubation with mAbs specific for mouse CD4 and CD8 conjugated to R-Phycoerythrin and Red 613, respectively (GIBCO BRL, Gaithersburg, MD). Single-color (for Eb\(^a\)) and three-color (for V\(\beta\) TCR) flow cytometric analysis was performed using a FACS® IV flow cytometer (Becton Dickinson & Co., Mountain View, CA).

**Induction and Quantification of Arthritis.** Bovine CII (BII), prepared as previously described (3), was dissolved in 0.1 M acetic acid and at a concentration of 2 mg/ml then emulsified 1:1 with complete Freund's adjuvant H37 Ra (Difco Laboratories, Detroit, MI). Mice received 100 μg of cold emulsion intradermally in the base of the tail. Mice were monitored three times a week from week 3 to 9 post immunization for the onset and development of CIA. The arthritic severity of all four limbs was determined as previously described (3) using a grading system for each paw based on a scale of 0–3 as follows: 0 = normal; 1 = redness and swelling in paws or toes; 2 = deformity in paw; and 3 = ankylosis in the affected joint. The clinical score from each limb was summed thus giving a severity range of 0–12 per mouse. The mean arthritic severity was calculated using arthritic animals only.

**Measurement of Serum Anti-CII Antibody.** Mice were bled via the tail artery on day 35 post immunization and the level of anti-mouse CII (MII) and anti-BII Abs in serum were determined using a standard ELISA technique (17). Sera was tested at 1/100 dilutions and compared with a pooled positive control sera. The data is expressed as mean OD ± SD.

**Statistical Analysis.** Arthritis incidence between groups was analyzed using chi-square test with Yates' correction. Antibody levels were compared using the Student's t test.

**Results**

Unlike mice carrying the standard H-2\(^d\) haplotype (B10.Q, DBA/1), B10.RQB3 recombinant mice synthesize the E\(\alpha\)\(d\) molecule. The introduction of a 15.7-kb DNA fragment containing the entire Eb gene from the H-2\(^d\) haplotype was sufficient to induce the expression of H-2E molecules in these mice. Flow cytometric analysis showed that the level of surface expression of Eb\(^a\) molecule in the 15.7 transgene positive (Eb\(^a\)+) mice was comparable to the expression of the same molecule in mice of the H-2\(^d\) haplotype (Fig. 1). Expression of Eb\(^a\)E\(\alpha\) in positive control animals (B10.D2) was 54% whereas the expression of Eb\(^a\)E\(\alpha\) in 15.7 Eb\(^d\)+ B10.RQB3 mice was 52%. Negligible staining (<1%) was detected in Eb\(^a\) transgene negative (Eb\(^a\)-) littermates and B10 control (H-2\(^b\)) mice. Tissue distribution of the Eb transgene was comparable to the endogenous molecule in E positive strains of mice (data not shown).

To investigate the effect of H-2E molecule on the susceptibility to CIA, B10.RQB3 15.7 Eb\(^d\)+ and Eb\(^d\)- littermates were immunized with bovine CII in CFA. At 9 wk post immunization, the incidence of arthritis in Eb\(^d\)- mice was significantly lower than in Eb\(^d\)- littermates (p <0.01, Table 1). Among the three Eb\(^d\) mice that developed CIA, the extent of arthritis was mild as indicated by arthritic scores from 1 to 2. In contrast, a majority of arthritic Eb\(^d\)- littermates displayed severe swelling in at least two limbs, and their arthritic scores ranged from 1 to 8.

The inhibitory effect of the 15.7 Eb\(^d\) transgene was also apparent in the development of antibody against CII. Analysis of sera at a 1/100 dilution showed a 32% reduction in mean OD of BII-reactive Ab mice and a 45% decrease in reactivity against homologous MII Ab in Eb\(^d\)+ vs. Eb\(^d\)- littermates (p <0.001, Table 1).

Through flow cytometry, deletion in V\(\beta\)5.1, 5.2, and 11 bearing T cell populations was found in both CD4 and CD8 subsets for Eb\(^d\)+ and Eb\(^d\)- mice (Table 2). No significant difference in the V\(\beta\) TCR expression was evident between the two groups with the exception of CD4+, V\(\beta\)11+ T cells, which were further decreased in Eb\(^d\)- mice. The deletion of V\(\beta\)5 and V\(\beta\)11 T cells was expected in Eb\(^d\) transgene negative B10.RQB3 mice since they express an interisotypic A\(\alpha\)/E\(\alpha\) molecule known to delete some TCR V\(\beta\)-bearing T cell populations (18).

To confirm our observations, we used a second line of
Table 1. Resistance to CIA in B10.RQB3-Eβ 15.7 Transgenic Mice*

| Mice            | Incidence | Arthritis severity | Anti-CII Ab |
|-----------------|-----------|--------------------|-------------|
|                 | mean ± SD |                    | BII         | MII         |
| Eβ Tg Positive  | 3/13      | 1.3 ± 0.6          | 0.35 ± 0.05 | 0.12 ± 0.1  |
|                 | p <0.001  |                    | p <0.001    | p <0.001    |
| Eβ Tg Negative  | 16/20     | 3.8 ± 2.0          | 0.51 ± 0.06 | 0.22 ± 0.08 |

* Mice were immunized with 100 µg BII in CFA on day 0 and monitored regularly for the onset and development of CIA.

Table 2. Peripheral Expression of Vβ TCR in Transgenic B10.RQB3-Eβ Positive and B10.RQB3-Eβ Negative Mice*

| Vβ   | CD4  | CD8  | CD4  | CD8  |
|------|------|------|------|------|
| Vβ2  | 5.2 ± 1.0 | 4.9 ± 1.9 | 5.1 ± 1.1 | 3.9 ± 2.4 |
| Vβ4  | 6.5 ± 0.3 | 5.5 ± 0.4 | 7.3 ± 0.3 | 5.8 ± 0.2 |
| Vβ5.1.2 | 0.4 ± 0.1 | 5.1 ± 0.3 | 1.0 ± 0.5 | 7.4 ± 0.5 |
| Vβ6  | 7.8 ± 1.9 | 12.6 ± 1.3 | 4.6 ± 0.9 | 13.1 ± 1.3 |
| Vβ7  | 2.2 ± 0.3 | 5.9 ± 0.1 | 3.6 ± 1.1 | 9.4 ± 3.8 |
| Vβ8.2 | 14.5 ± 0.6 | 7.4 ± 0.8 | 16.4 ± 0.5 | 7.1 ± 0.6 |
| Vβ9  | 1.9 ± 0.1 | 5.2 ± 1.8 | 1.7 ± 0.1 | 6.3 ± 1.6 |
| Vβ11 | 0.6 ± 0.3 | 1.1 ± 0.8 | 1.9 ± 1.2 | 1.9 ± 1.5 |
| Vβ14 | 7.3 ± 0.5 | 2.9 ± 0.5 | 6.9 ± 0.4 | 2.4 ± 0.2 |

* Normal transgenic B10.RQB3-Eβ+ and B10.RQB3-Eβ- mice were bled and their PBL stained for Vβ TCR expression as detailed in Materials and Methods. The mean percentage was calculated based on four animals per group.

Table 3. Protection against CIA in B10.RQB3-Eβ 10.2 Transgenic Mice*

| Mice            | Incidence | Arthritis severity | Anti-CII Ab |
|-----------------|-----------|--------------------|-------------|
|                 | mean ± SD |                    | BII         | MII         |
| Eβ Tg positive  | 4/14      | 1.7 ± 1.0          | 0.22 ± 0.03 | 0.24 ± 0.1  |
|                 | p <0.03   |                    | p <0.01     | p <0.01     |
| Eβ Tg negative  | 7/11      | 3.3 ± 1.7          | 0.35 ± 0.08 | 0.41 ± 0.10 |

* Mice were immunized with 100 µg BII in CFA on day 0 and monitored regularly for the onset and development of CIA.

Similar to B10.RQB3-Eβ 10.2+ mice, B10.RQB3-Eβ 10.2+ mice showed a significant reduction in the incidence and severity of arthritis vs. Eβ- littermates after immunization with bovine CII (Table 3). Also, among the four Eβ+ 10.2+ mice that developed CIA, the severity of arthritis was mild compared to Eβ+ 10.2− littermates. Finally, like in Eβ+ 15.7 mice, analysis of sera at a 1/100 dilution in Eβ+ 10.2+ animals showed a 37% reduction in mean OD of BII-reactive Ab and a 42% decrease in reactivity against homologous MII Ab vs. Eβ- littermates.
of Eβd molecule in (B10.RQB3 × B10.D2)F1 mice was similar to B10.RQB3-Eβd+ and B10.D2 mice (data not shown). The incidence of CIA was compared between (B10.RQB3 × B10.D2)F1 mice and B10.RQB3-Eβd+ and Eβd- transgenic mice. Like B10.RQB3-Eβd+ animals, (B10.RQB3 × B10.D2)F1 mice showed a significant reduction in the incidence of arthritis versus B10.RQB3-Eβd- mice (Table 4). However, in (B10.RQB3 × B10.D2)F1 mice, the decrease of CIA appeared intermediate compared with B10.RQB3-Eβd+ animals (40% vs. 25%). This observation shows an inhibitory role of Eβd molecule on CIA coded by an endogenous gene as well as a transgene.

### Discussion

Here we report for the first time the generation of mice presenting the unique feature of being H-2Aβ positive and expressing an H-2E molecule at the same time. As expected, B10.RQB3 mice are CIA susceptible because they express IAβ (18). In this strain, E molecules are not expressed since Eb is nonfunctional (7, 8). By introducing an Eb transgene, we induced expression of E molecules in B10.RQB3 mice, resulting in a dramatic reduction in the incidence of CIA as well as the level of anti-BII and anti-MII Ab in the serum of Eβd+ transgenic mice. Analysis of Vβ TCR expression on PBL demonstrated the deletion of Vβ5.1, Vβ5.2, and Vβ11 bearing T cells in both Eβd+ and Eβd- B10.RQB3 mice. Although the presence of the Eβd molecule justifies these results in E positive mice (20, 21), it has been demonstrated that the Ea/Ab heterodimer expressed in B10.RQB3 (Eβd-) mice plays a similar role to Ea/EB dimers in the deletion of several Vβ bearing T cell populations (18).

Previous studies in other mouse models of autoimmune diseases have demonstrated that the expression of a functional E molecule can play a protective role (22). By introducing an Ea transgene into nonobese diabetic (NOD) mice, the restored expression of E molecules led to protection against insulin-dependent diabetes mellitus (23-25). Also, expression of an Ea transgene led to a dramatic reduction in the development of autoimmune glomerulonephritis in BXSB mice (26). There are several distinct differences between our studies and the earlier work in NOD and BXSB mice. First, in the aforementioned studies, expression of E molecules was restored by introduction of a transgene derived for the non-polymorphic Ea gene. In our studies in CIA, we restored expression of E molecules using a polymorphic Eb gene. Second, Merino et al. (26) reported that resistance to glomerulonephritis in Eoα transgenic BXSB mice was likely due to an exceedingly high copy number (>&50) of Eα transgene. Southern blot analysis of our two lines of B10.RQB3-Eβd transgenic mice, 15.7 and 10.2, revealed that the copy number of Ebα transgene was >4-8 and 5-10, respectively. Finally, expression of E molecules in heterozygous H-2b/d BXSB mice did not protect these animals from the development of autoimmune disease (27). Likewise, Podolin et al. (28) showed that progeny of an (NOD × NOD.H-2k)F1 cross were not protected from the development of diabetes.

In our studies, we observed that (B10.RQB3 × B10.D2)F1 mice showed a significant reduction in the incidence of CIA vs. B10.RQB3 animals (Table 4). Therefore, through both transgenic and conventional genetic techniques, it appears that introduction of an Ebα gene can alter susceptibility to CIA.

Several nonmutually exclusive mechanisms may account for the protective effect of Eβd in CIA. H-2Eβd expression could modulate the T cell repertoire by presenting a "tolerogenic" peptide which leads to the deletion or regulation of arthritogenic T cell clones. It is also possible that a Th1 to Th2 switch occurs in the CIA response in the context of the Eβd molecule. It has been shown that the administration of the Th2-derived cytokine IL-4 could facilitate remission of CIA in DBA/1 (H-2a) mice (29). Finally, it is possible that H-2Aβ mediates the presentation of Eβ peptides derived from the Eβd molecule itself which, in turn, modulates the arthritogenic response. Although studies directed towards characterizing naturally processed peptides associated with class II molecules have shown that a portion of peptides bound to H-2A molecules are derived from Ecα chains (30), the contribution of Eβ-derived peptides is not clear. Likewise, the scope of self-peptides associated with H-2Aβ molecules, which is of interest in our system, remains to be elucidated.

Of importance, B10.RIII (H-2e) mice are susceptible to CIA despite expression of functional E molecules (31). It is possible that, unlike Eβd, the Eβ molecule does not lead to protection in CIA. Previously, we found that (B10.Q × B10.K)F1 mice are CIA susceptible, suggesting that Eβ does not play a protective role. Thus, polymorphism of the Eb gene, in the context of particular haplotypes, may play a role in determining self tolerance or autoimmunity. Indeed, preliminary studies suggest that the protective effect of the Eβd molecule in CIA is q haplotype specific; no difference was observed in arthritis susceptibility between transgenic positive and negative offspring of a (B10.RQB3-Eβd × B10.RIII)F1 cross (our unpublished observations). In B10.RIII mice, H-2E could be functionally equivalent to DR1 and DR4 subtypes associated in human with RA. Presentation of DRβ
peptide (Eβ peptide) by DQ molecule (H-2A equivalent) may explain observed differences in the role of DR molecules in RA. Variants of the HLA-DR4 family and HLA-DR1 subtypes may be deficient in mediating protection, analogous to H-2Eβ in mice. In closing, our data is the first demonstration of a protective role of Eβ molecules in murine CIA. Experiments are currently underway to further delineate the role of H-2Eβ molecules in CIA and understand the mechanisms involved in the protection. These studies will shed light on the possible role of DR molecules in human RA.

We thank Drs. J. Baisch and C. Krco for their comments, S. Savarirayan for producing the transgenic mice and J. Hanson for breeding of the mice.

These studies were supported by National Institutes of Health grants AR-30752. The research of Dr. Gonzalez-Gay and Dr. Nabozny has been supported by fellowships from “Fondo de Investigaciones Superiores” 93/5348 (Spain), and The Arthritis Foundation, respectively.

Address correspondence to Dr. Chella S. David, Department of Immunology, Gugg. 309, Mayo Clinic, Rochester, MN 55905.

Received for publication 21 March 1994 and in revised form 30 June 1994.

References
1. Trentham, D.E., A.S. Townes, A.H. Kang, and J.R. David. 1978. Humoral and cellular sensitivity to collagen in type II collagen-induced arthritis in rats. J. Clin. Invest. 61:89.
2. Trentham, D.E. 1982. Collagen induced arthritis as a relevant model for rheumatoid arthritis. Evidence pro and con. Arthritis. Rheum. 25:911.
3. Wooley, P.H., H.S. Luthra, M.M. Griffiths, J.M. Stuart, A. Huse, and C.S. David. 1985. Type II collagen induced arthritis in mice. IV. Variations in immunogenetic regulation provide evidence for multiple arthritogenic epitopes on the collagen molecule. J. Immunol. 135:2443.
4. Wooley, P.H., H.S. Luthra, J.M. Stuart, and C.S. David. 1981. Type II collagen induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J. Exp. Med. 154:688.
5. Hood, L., M. Steinmetz, and B. Malissen. 1983. Genes of the major histocompatibility complex of the mouse. Annu. Rev. Immunol. 1:529.
6. Begovich, A.B., T.H. Vu, and P.P. Jones. 1990. Characterization of the molecular defects in the mouse Eβ and Eα genes. Implications for the origin of MHC polymorphism. J. Immunol. 144:1957.
7. Mathis, D.J., C. Benoist, V.E. Williams II, M. Kanter, and H.O. McDevitt. 1983. Several mechanisms can account for defective Ea gene expression in different mouse haplotypes. Proc. Natl. Acad. Sci. USA. 80:273.
8. Holmdahl, R., M. Karlsson, M.E. Andersson, L. Rask, and T. Andersson. 1989. Localization of a critical restriction site on the I-Ab chain is important for a restricted antigen presentation in helper T-cell hybridomas. Proc. Natl. Acad. Sci. USA. 86:9475.
9. Nepom, G.T., and B.S. Nepom. 1992. Prediction of susceptibility to rheumatoid arthritis by human leukocyte antigen genotyping. Rheum. Dis. Clin. North. Am. 18:785.
10. Weyand, C.M., and J.J. Goronzy. 1993. Prognosis in rheumatoid arthritis: applying new technologies to old questions. J. Rheumatol. 20:1817.
11. Stastny, P. 1978. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N. Engl. J. Med. 298:869.
12. Winchester, R., E. Dwyer, and S. Rose. 1992. The genetic basis of rheumatoid arthritis. The shared epitope hypothesis. Rheum. Dis. Clin. North. Am. 18:761.
13. Folsom, V., D. Gay, and S. Tonegawa. 1985. The β1 domain of the mouse Eβ chain is important for a restricted antigen presentation to helper T-cell hybridomas. Proc. Natl. Acad. Sci. USA. 82:1678.
14. Wei, B.-Y., J. Martin, S. Savarirayan, R. Little, and C.S. David. 1990. Transgenic mice with MHC class II genes: the use in the study of allelic α/β chain pairing and the production of engineered mice with mutant I-A genes. In Transgenic mice and mutants in MHC research. I.K. Egorov, and C.S. David, editors. Springer-Verlag, Berlin Heidelberg. 237.
15. Nabozny, G.H., M.J. Bull, J. Hanson, M.M. Griffiths, H.S. Luthra, and C.S. David. 1994. Collagen-induced arthritis in T cell receptor VB congenic B10.Q mice. J. Exp. Med. 180:517.
16. Ozato, K., N.M. Mayer, and D.H. Sachs. 1982. Monoclonal antibodies to mouse major histocompatibility complex antigens. IV. A series of hybridoma clones producing anti-H-2β antibodies and a examination of expression of H-2β antigens on the surface of these cells. Transplantation (Baltimore). 34:113.
17. Griffiths, M.M., M.A. Cremer, D.S. Harper, S. McColl, and G.W. Cannon. 1992. Immunogenetics of collagen-induced arthritis in rats. Both MHC and non-MHC gene products determine the epitope specificity of immune response to bovine and chick type II collagen. J. Immunol. 149:509.
18. Anderson, G.D., and C.S. David. 1989. In vivo expression and function of hybrid Ia dimers (Eα, Aα) in recombinant and transgenic mice. J. Exp. Med. 170:1003.
19. Glimcher, L.H., and C.J. Kara. 1992. Sequences and factors: a guide to MHC class-II transcription. Annu. Rev. Immunol. 10:13.
20. Bill, J., O. Kanagawa, D.I. Woodland, and E. Palmer. 1989. The MHC molecule I-E is necessary but not sufficient for the
clonal deletion of Vβ11-bearing T cells. J. Exp Med. 169:1405.
21. Woodland, D., J.P. Happ, J. Bill, and E. Palmer. 1990. Re-
requirement for cotolergenic gene products in clonal deletion
of I-E reactive T cells. Science (Wash. DC). 247:964.
22. Christadoss, P., C.S. David, M. Shenoy, and S. Keve. 1990.
Eco4 transgene in B10 mice suppresses the development of my-
asthenia gravis. Immunogenetics. 31:241.
23. Nishimoto, H., H. Kikutani, K. Yamamura, and T. Kishimoto.
1987. Prevention of autoimmune insulinitis by expression of
I-E molecules in NOD mice. Nature (Lond.). 328:432.
24. Lund, T., L. O'Reilly, P. Hutchings, O. Kanagawa, E. Simpson,
R. Gravely, P. Chandler, J. Dyson, J.K. Picard, A. Edwards,
et al. 1990. Prevention of insulin-dependent diabetes mellitus
in non-obese diabetic mice by transgenes encoding modified
I-A β chain or normal I-E α-chain. Nature (Lond.). 345:727.
25. Uehira, M., M. Uno, T. Kurner, H. Kikutani, K. Mori, T.
Inomoto, T. Ueda, J. Miyazaki, H. Nishimoto, T. Kishimoto,
and K. Yamamura. 1989. Development of autoimmune insuli-
nitis is prevented in Eco4 but not in Aβα NOD transgenic
mice. Int. Immunol. 1:209.
26. Merino, R., M. Iwamoto, L. Fossati, P. Muniesa, K. Araki,
S. Takahashi, J. Huarte, K.-I. Yamamura, J.-D. Vassalli, and
S. Izui. 1993. Prevention of systemic lupus erythematosus in
autoimmune BXSB mice by a transgene encoding I-E α chain.
J. Exp Med. 178:1189.
27. Merino, R., L. Fossati, M. Lacaut, R. Lemoine, M. Higaki,
and S. Izui. 1992. H-2 linked control of the Yaa gene-induced
acceleration of lupus-like autoimmune disease in BXSB mice.
Eur. J. Immunol. 22:295.
28. Podolin, P.L., A. Pressey, N.H. DeLarato, P.A. Fischer, L.B.
Peterson, and L.S. Wicker. 1993. I-Eα nonobese diabetic mice
develop insulinitis and diabetes. J. Exp Med. 178:793.
29. Marcelletti, J.F., J.-I. Ohara, and D.H. Katz. 1991. Collagen-
induced arthritis in mice. Relationship of collagen-specific and
total IgE-synthesis to disease. J. Immunol. 147:4185.
30. Hunt, D.F., H. Michel, T.A. Dickinson, J. Shabanowitz, A.L.
Cox, K. Sakaguchi, E. Appella, H.M. Grey, and A. Sette. 1992.
Peptides presented to the immune system by the murine class
II major histocompatibility complex molecule I-A4. Science
(Wash. DC). 256:1817.
31. Klein, J. 1986. The protein. Mutations in H-2E loci. In Nat-
ural History of The Major Murine Class II Major Histocom-
patibility Complex Molecule I-A4. Histocompatibility Com-
plex. J. Klein, Editor. Wiley Interscience Publication, New
York. 216.